DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 022200/S-012
NDA 022200/S-013

SUPPLEMENT APPROVAL

AstraZeneca AB
Attention: Cindy Cao, Ph.D.
Associate Director, CV & Metabolics
Global Regulatory & Safety Sciences – US
Bristol-Meyers Squibb
PO Box 4000 (Mail Stop: D22-06)
Princeton, NJ 08543-4000

Dear Dr. Cao:

Please refer to your Supplemental New Drug Applications (sNDA) dated April 25, 2014 (S-012) and April 30, 2014 (S-013), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Bydureon (exenatide extended-release) for injectable suspension.

We acknowledge receipt of your amendments dated May 22, 2014.

We also refer to our letter dated March 27, 2014, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Bydureon (exenatide extended-release). This information pertains to the risk of injection site reactions.

> **S-012** This supplemental new drug application provides for revisions to the Prescribing Information and Medication Guide for Bydureon (exenatide extended-release), consistent with our March 27, 2014, letter.

We also refer to our letter dated February 28, 2014, requesting revisions to the Instructions for Use for the single-dose tray containing 2 mg vial presentation of Bydureon (exenatide extended-release).

> **S-013** This supplemental new drug application provides for revisions to the Instructions For Use for the single-dose tray containing 2 mg vial presentation of Bydureon (exenatide extended-release), consistent with our February 28, 2014, letter.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revisions listed below.

Addition of Recent Major Changes in the Highlights section of the Prescribing Information

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling, (text for Prescribing Information, Medication Guide, and Instructions for Use) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Pooja Dharia, Pharm.D., Regulatory Project Manager, at (301) 796-5332.

Sincerely,

{See appended electronic signature page}

Jennifer Rodriguez Pippins, M.D., M.P.H.
Deputy Director for Safety (Acting)
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURES:
- Prescribing Information
- Medication Guide
- Instruction for Use for single-dose tray presentation
- Instructions for Use for pen presentation (version approved on February 28, 2014)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JENNIFER R PIPPINS
05/22/2014